Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

DDW: Esomeprazole Provides More Effective Intragastric Acid Control Than All Other Proton Pump Inhibitors By Bruce Wilson Special to DG News ATLANTA, GA -- May 22, 2001 -- Esomeprazole (40 mg), a proton pump inhibitor (PPI) has been demonstrated to provide superior intragastric acid control compared to standard doses of omeprazole (20 mg), pantoprazole (40 mg), lansoprazole (30 mg) or rabeprazole (20 mg). Research supporting this was presented at the Digestive Diseases Week being held here in Atlanta, Georgia. Four separate randomized, cross-over studies were conducted in Sweden and Switzerland, comparing esomeprazole 40 mg with the other agents. In each study, participants received a single dose of a PPI each morning, 30 minutes before breakfast, for five days with a washout period of at least 14 days between treatments. In study A, patients with gastro-esophageal reflux (GERD) were given esomeprazole or omeprazole. In study B, a similar group of patients were given esomeprazole or pantoprazole. In study C, a group of normal volunteers were given emeprazole or lansoprazole. In study D, normal volunteers were given esomeprazole or rabeprazole. On the fifth day of treatment, each subject was given a continuous 24-hour intragastric pH recording to determine the percentage of time with intragastric pH >4.0 (the primary endpoint). According to Dr. Kerstin Röhss, AstraZeneca R&D Molndal, Mölndal, Sweden, esomeprazole resulted in a longer time with intragastric pH >4.0 for the 24-hour period on treatment day five. Also, the proportion of subjects with intragastric pH > 4.0 for 12 hours and 16 hours was significantly higher for esomeprazole than for each of the other PPIs on day five. In the breakdown by individual study, the mean difference in the time with pH >4.0 over 24 hours was 26.1 percent in study A (p<0.0001), 22.2 percent in study B (p<0.001), 12.4 percent in study C (p<0.001), and 15.8 percent in study D (p=0.005). All PPIs were well-tolerated and showed no adverse effects. Dr. Röhss and her colleagues explained that esomeprazole is the first proton pump inhibitor to be developed for clinical use as an optical isomer. It has a higher systemic bioavailability than omeprazole, which translates into greater and more sustained intragastric acid suppression. E-mail this page to a friend or colleague! To print, use this version